|
|
|
|
|
HPLC System. |
Agilent 1100 |
|
Column |
STYROSä 2R/XH 4.6 X 50 mm |
|
Mobile Phase |
A: 0.075% TFA in H2O |
|
Flow rate |
1 ml/min (360 cm/hr) |
|
Gradient |
5% B for 0.3 min., to 100% B in 4 min. |
|
Temperature |
37°C |
|
Detection |
252 nm |
|
Injection volume |
25 ml |
|
Sample: |
As indicated. |
The metabolisms of vinca alkaloids are known to be mediated by hepatic cytochrome P450 isoenzymes in the CYP3A subfamily. It is therefore important to consider any hepatic dysfunction as well as any potent metabolic inhibitor when administering the drug to these patients.
The metabolites of Vinorelbine in excess doses have been detected in the blood plasma and urine. However, in therapeutic doses of up to 30 mg/m2, hardly any metabolite can be detected either in the blood or in the urine.
The present application shows how one can effectively gauge the excess drug after its intravenous administration during a short chromatographic run.
Judging by the patient’s blood count, Vinorelbine’s effect can be seen for up to 14 days. However, no detectable peek can be recorded after 12 hrs during chromatographic run using urine samples.

Copyright © 1997-2009
OraChrom, Inc.
|